Sanofi Appoints David Meeker Chief Executive Officer of Genzyme
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) announced the appointment of David Meeker as Chief Executive Officer of Genzyme, a Sanofi company, effective November 1, 2011. He will report to Christopher A. Viehbacher, Chief Executive Officer of Sanofi, and will join the Group Management Committee. Christopher A. Viehbacher will retain the position of Chairman, Genzyme.
AIN457 provided rapid and significant relief of symptoms in up to 81% of patients with psoriasis
- Details
- Category: Novartis
Novartis has announced positive results from three Phase II trials showing that AIN457 (secukinumab) produced a quick and significant improvement of symptoms in patients with moderate-to-severe plaque psoriasis. The results were presented at the annual European Academy of Dermatology and Venereology (EADV) Congress, in Lisbon, Portugal.
Lilly Reports Third-Quarter 2011 Results
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) announced financial results for the third quarter of 2011. In the third quarter of 2011, worldwide total revenue was $6.148 billion, an increase of 9 percent compared with the third quarter of 2010.
Abbott Reports Strong Ongoing Third Quarter Results
- Details
- Category: Abbott
Abbott's worldwide sales increased 13.2 percent to $9.8 billion, including a favorable 5.3 percent effect of foreign exchange. Proprietary Pharmaceuticals sales increased 13.5 percent in the quarter.
Bristol-Myers Squibb Announces Changes in Senior Management Team
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) announced a series of related changes within its Senior Management Team. Giovanni Caforio has been promoted to president, U.S. Pharmaceuticals.
Abbott to Separate into Two Leading Companies in Diversified Medical Products and Research-Based Pharmaceuticals
- Details
- Category: Abbott
Today Abbott (NYSE: ABT) announced that it plans to separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals.
Roche reports positive study of Herceptin given by subcutaneous injection
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Phase III HannaH study demonstrated comparable efficacy of a new, investigational subcutaneous (SC) formulation of Herceptin (trastuzumab) to the standard intravenous (IV) infusion of Herceptin in women with HER2-positive early breast cancer.
More Pharma News ...
- Novartis drug Gilenya® (fingolimod) has more than 20,000 patient-years of exposure
- Bayer HealthCare and Onyx Pharmaceuticals Restructure Global Oncology Partnership
- Roche achieves significant progress with personalised healthcare
- Humana and Pfizer Form Research Partnership
- New Study Shows Cialis® Significantly Improved Study Endpoints
- Bristol-Myers Squibb Foundation Announces Collaboration with World Health Organization's Stop TB Department
- AstraZeneca increases investment in China with new $200 million manufacturing facility